Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2010 1
2011 1
2012 1
2015 1
2016 2
2017 4
2019 4
2020 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
FutureTox III: Bridges for Translation.
Juberg DR, Knudsen TB, Sander M, Beck NB, Faustman EM, Mendrick DL, Fowle JR 3rd, Hartung T, Tice RR, Lemazurier E, Becker RA, Fitzpatrick SC, Daston GP, Harrill A, Hines RN, Keller DA, Lipscomb JC, Watson D, Bahadori T, Crofton KM. Juberg DR, et al. Among authors: keller da. Toxicol Sci. 2017 Jan;155(1):22-31. doi: 10.1093/toxsci/kfw194. Epub 2016 Oct 25. Toxicol Sci. 2017. PMID: 27780885 Free PMC article.
Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development.
Roth SE, Avigan MI, Bourdet D, Brott D, Church R, Dash A, Keller D, Sherratt P, Watkins PB, Westcott-Baker L, Lentini S, Merz M, Ramaiah L, Ramaiah SK, Stanley AM, Marcinak J. Roth SE, et al. Among authors: keller d. Clin Pharmacol Ther. 2020 Feb;107(2):333-346. doi: 10.1002/cpt.1571. Epub 2019 Sep 14. Clin Pharmacol Ther. 2020. PMID: 31314926 Free PMC article. Review.
The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
MacDonald J, French JE, Gerson RJ, Goodman J, Inoue T, Jacobs A, Kasper P, Keller D, Lavin A, Long G, McCullough B, Sistare FD, Storer R, van der Laan JW. MacDonald J, et al. Among authors: keller d. Toxicol Sci. 2004 Feb;77(2):188-94. doi: 10.1093/toxsci/kfh037. Epub 2003 Dec 2. Toxicol Sci. 2004. PMID: 14657512 Review.
Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment.
Bassan A, Steigerwalt R, Keller D, Beilke L, Bradley PM, Bringezu F, Brock WJ, Burns-Naas LA, Chambers J, Cross K, Dorato M, Elespuru R, Fuhrer D, Hall F, Hartke J, Jahnke GD, Kluxen FM, McDuffie E, Schmidt F, Valentin JP, Woolley D, Zane D, Myatt GJ. Bassan A, et al. Among authors: keller d. Front Toxicol. 2024 Apr 5;6:1370045. doi: 10.3389/ftox.2024.1370045. eCollection 2024. Front Toxicol. 2024. PMID: 38646442 Free PMC article.
Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective.
Ewart L, Fabre K, Chakilam A, Dragan Y, Duignan DB, Eswaraka J, Gan J, Guzzie-Peck P, Otieno M, Jeong CG, Keller DA, de Morais SM, Phillips JA, Proctor W, Sura R, Van Vleet T, Watson D, Will Y, Tagle D, Berridge B. Ewart L, et al. Among authors: keller da. Exp Biol Med (Maywood). 2017 Oct;242(16):1579-1585. doi: 10.1177/1535370217715441. Epub 2017 Jun 16. Exp Biol Med (Maywood). 2017. PMID: 28622731 Free PMC article.
19 results